Table 4 Studies evaluating pathological complete response (pCR) rates in ER-low positive BCs treated with neoadjuvant chemotherapy (studies reporting ER expression as Allred score or H-score were also included).
ER subgroups | Number of Patients in each subgroup | % pCR | OR (95%CI)/p-value | |
|---|---|---|---|---|
Gloyeske et al. (2014)20 | ER-low positive (H-scores of 1–100) | 18 | 33% | – |
Fujii et al. (2017)7 | ER < 1% | 932 | 26% | 0.95 (0.64–1.40)/p = 0.792 |
ER1–9% | 171 | 28% | Ref | |
ER ≥ 10% | 3055 | 7% | – | |
Landmann et al. (2018)8 | ER-negative (H-score = 0) | 141 | 26% | p = 0.1722 |
Low ER+ (H-score 1–100) | 41 | 37% | Ref | |
Moderate ER+ (H-score 101–200) | 47 | 11% | – | |
High ER+ (H-score 201–300) | 98 | 4% | – | |
Ohara et al. (2019)6 | ER < 1% | 32 | 41% | p = 0.296 |
ER1–9% | 16 | 25% | Ref | |
ER ≥ 10% | 108 | 7% | – |
